Association of Continuous-Equivalent Urea Clearances with Death Risk in Intermittent Hemodialysis by Vartia, Aarne et al.
Research Article
Association of Continuous-Equivalent Urea Clearances with
Death Risk in Intermittent Hemodialysis
Aarne Vartia,1 Heini Huhtala,2 and Jukka Mustonen3,4
1Savonlinna Central Hospital, 57120 Savonlinna, Finland
2School of Health Sciences, University of Tampere, 33014 Tampere, Finland
3School of Medicine, University of Tampere, 33014 Tampere, Finland
4Tampere University Hospital, 33521 Tampere, Finland
Correspondence should be addressed to Aarne Vartia; aarne.vartia@gmail.com
Received 19 January 2016; Accepted 30 March 2016
Academic Editor: Deepak Malhotra
Copyright © 2016 Aarne Vartia et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Several reports describe favorable results from frequent hemodialysis, but due to the lack of unequivocal dosemeasures
it is not clear whether the benefits are due to more efficient toxin removal or other factors. Methods. The associations with death
risk of six continuous-equivalent urea clearance measures were compared in 57 conventional in-center hemodialysis treatment
periods of 51 patients, together 114 patient years. The double pool dose measures were calculated with the Solute-Solver program
and separately scaled to urea distribution volume or normalized with body surface area. Results. Mortality associated significantly
with equivalent renal urea clearance (EKR) scaled to urea distribution volume (𝑉) (𝑝 = 0.033) and with EKR normalized with
body surface area (BSA) (𝑝 = 0.044) but not with 𝑉-scaled (𝑝 = 0.059) nor BSA-normalized (𝑝 = 0.183) standard clearance
(stdK). Women had significantly higher normalized protein catabolic rate (nPCR), EKR/𝑉, and stdK/𝑉 than men but slightly
lower BSA-normalized dose measures and lower mortality. Protein catabolic rate and dialysis dose correlated positively with each
other and with survival. Conclusions. The prognostically most valid continuous-equivalent clearance in the present material was
EKR/𝑉, calculated from double pool urea generation rate, distribution volume, and time-averaged concentration.
1. Introduction
Survival correlates with urea-based hemodialysis session
dose in many large registry studies (Lowrie et al. [1]: 43,334
patients, Port et al. [2]: 84,936 patients, and Miller et al. [3]:
88,153 patients) in conventional thrice-weekly schedule, but
in the randomized controlled HEMO trial mean equilibrated
K𝑡/𝑉 (eK𝑡/𝑉) 1.53 did not result in a significantly better
outcome than 1.16 [4].
Intermittent hemodialysis treatments can be compared
to each other by the session dose measures URR, K𝑡, K𝑡/𝑉,
and eK𝑡/𝑉 only if the treatment frequency is equal. Several
observational studies, referred to in [5, 6], and the random-
ized controlled FHN trial [7] describe positive results from
frequent (“daily”) hemodialysis. However, the role of solute
removal efficiency remains obscure.
Urea distribution volume (𝑉) is an essential variable
in kinetic modeling and can be used as a representative
of patient size, a scaling factor. However, it may have also
an independent effect on outcome [1, 8], which weakens
the value of K𝑡/𝑉 as a prognostic factor. BSA has recently
been recommended for scaling of dialysis dose similarly
as in expressing the glomerular filtration rate [9]. 𝑉-scaled
dosing may result in suboptimal outcome in women and
children.
Equivalent renal urea clearance (EKR, Casino and Lopez)
[10] and standard clearance (stdK, Gotch) [11, 12] take
treatment frequency and residual renal function (RRF) into
account and they were intended for use in comparing dialysis
doses in different schedules and for continuous dialysis and
renal function [13, 14].
RRF may contribute significantly to the total weekly
solute removal [14] but only minimally (usually <1%) to the
delivered K𝑡/𝑉 or URRmeasured from blood samples. Renal
clearance (Kr) can be added mathematically to session K𝑡/𝑉
[15–17]. Continuous-equivalent clearance based on UKM
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Table 1: Association of patient characteristics and dialysis dose measures with death risk in 57 hemodialysis treatment periods of 51 patients.
Mean SD Min Max Univariate
𝑝 OR 95% CI
Age Years 61.6 15.5 16.7 91.6 0.103 1.038 0.993–1.085
Weight kg 75.1 18.2 44.2 123.6 0.525 0.989 0.957–1.023
BMI kg/m2 26.1 5.5 16.3 43.7 0.198 0.924 0.819–1.042
BSA m2 1.84 0.25 1.31 2.34 0.872 0.823 0.078–8.727
𝑉 L 31.8 6.7 20.5 50.3 0.637 1.021 0.936–1.113
nPCR g/kg/day 1.15 0.24 0.73 1.74 0.058 0.065 0.004–1.095
nKr mL/min/1.73m
2 1.7 1.4 0.0 6.0 0.861 0.963 0.631–1.469
nEKR mL/min/1.73m2 12.5 1.3 8.4 16.4 0.044 0.611 0.379–0.988
nstdK mL/min/1.73m2 8.5 1.0 6.2 12.2 0.183 0.638 0.330–1.235
nEKRant mL/min/1.73m2 15.1 2.3 8.3 20.3 0.113 0.806 0.617–1.053
nstdKant mL/min/1.73m2 10.2 1.6 6.1 14.3 0.232 0.785 0.527–1.168
EKR/𝑉 /week 4.35 0.64 2.36 5.82 0.033 0.326 0.117–0.912
stdK/𝑉 /week 2.93 0.39 1.73 3.88 0.059 0.205 0.040–1.060
fr /week 2.9 0.3 2.0 3.7 0.413 0.503 0.097–2.606
𝑡d h/week 13.5 2.3 7.7 18.4 0.077 0.786 0.602–1.027
Table 2: Hemodialysis treatment period durations and reasons for
discontinuation.
𝑁 % Duration (years)
Mean SD Min Max
Continuing 19 33.3 2.5 1.7 0.4 5.8
Death 16 28.1 2.3 1.6 0.6 6.9
Transplantation 8 14.0 1.4 1.3 0.6 4.6
Transfer to another unit 8 14.0 1.3 1.2 0.3 3.8
Transfer to peritoneal dialysis 3 5.3 2.1 1.4 0.7 3.5
Decision 3 5.3 0.8 0.3 0.6 1.1
The numbers include hemodialysis treatment periods ongoing on January
1, 1998 (from that date on), and incident periods during the nine-year
observation time until December 31, 2006 (unless terminated earlier).
includes Kr automatically. Renal function is “qualitatively”
better than dialysis with equal urea clearance [18].
In theory, the continuous-equivalent average clearance
based on double pool UKM and including RRF is fine, but
the best measure is the one most closely associated with
outcome. Only few earlier reports correlate mortality directly
with ECC [7, 19–22].The aimof the present preliminary study
was to compare the prognostic value of different continuous-
equivalent urea clearances as dialysis dose measures.
2. Subjects and Methods
The study is a retrospective registry analysis from a hospital
providing adult hemodialysis services in a district with
a catchment area of some 50,000 inhabitants in Eastern
Finland. The observation time was nine years, from January
1, 1998, to December 31, 2006. The material comprises 57
conventional in-center hemodialysis treatment periods of 51
patients, in total 114 patient years. Periods lasting under 90
days are not included. Patient characteristics are described
in Table 1. Table 2 presents the characteristics of the dialysis
treatment periods. “Decision” refers to a unanimous decision
by patient and physician to discontinue renal replacement
therapy.
Dosing of dialysis, including treatment frequency, was
prescribed by the first author on multiple criteria (weight,
hydration status, predialysis plasma urea concentration, and
other laboratory values, eK𝑡/𝑉 targets, and patient’s pref-
erences). Renal diagnosis, comorbidity, functional status,
waiting for transplantation, age, anticipated survival time,
and protein catabolic rate (PCR) were not used as dosing
criteria. The patients were encouraged by a dietician to use
a diet containing protein 1.2 g/kg/day, but the actual dietary
protein intake was not controlled.
Urea kinetic modeling with interdialysis urine collection
was performed monthly. Kr was interpolated from previous
andnextmeasurements if urine collection occasionally failed.
RRF was detected in 68% of UKM sessions. In 15% of them,
Kr was interpolated. The numbers describing the patient
characteristics and dialysis dose measures are means of each
treatment period.
Double pool UKM calculations were conducted with the
Solute-Solver program version 1.97 (July 2, 2010, with source
code) [23], accessed November 12, 2015: http://www.ureak-
inetics.org/.
Dialyzer mass area coefficient (K
0
𝐴) reported by the
dialyzer manufacturer is used in Solute-Solver in calculating
dialyzer clearance (Kd) from 𝑄b and 𝑄d with Michaels’
equation [24].
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Table 3: Dialysis treatment periods divided into two groups with approximately equal mean nPCR.
EKR/𝑉
𝑝 valueLow High
Mean SD Mean SD
Age Years 60.8 13.2 62.5 17.7 0.668
Weight kg 77.1 21.2 72.9 14.7 0.393
BMI kg/m2 26.5 6.5 25.7 4.4 0.595
BSA m2 1.86 0.27 1.81 0.22 0.441
𝑉 L 33.7 7.5 29.8 5.1 0.024
nPCR g/kg/day 1.19 0.28 1.12 0.19 0.283
nKr mL/min/1.73m
2 2.0 1.4 1.4 1.4 0.102
nEKR mL/min/1.73m2 12.1 1.5 13.0 1.0 0.005
nstdK mL/min/1.73m2 8.3 1.1 8.7 0.9 0.240
nEKRant mL/min/1.73m2 14.2 2.4 16.2 1.7 0.001
nstdKant mL/min/1.73m2 9.8 1.7 10.7 1.3 0.023
EKR/𝑉 /week 3.99 0.59 4.72 0.45 <0.001
stdK/𝑉 /week 2.75 0.38 3.12 0.30 <0.001
Treatment frequency /week 2.8 0.4 3.1 0.2 0.006
Treatment time h/week 12.6 2.5 14.4 1.7 0.003
Treatment periods 𝑛 29 28
Women % 31.0 46.4 0.233
Diabetics % 37.9 46.4 0.516
Ending with death % 37.9 17.9 0.092
Patient years 𝑛 49.8 64.5
Deaths 𝑛 11 5
Mortality /1000 py 221 78 0.049
Their definitions are described in the Appendix. EKR is based
on time-averaged urea concentration; stdK is based on aver-
age peak concentration. All include diffusion, convection,
and renal clearance.
2.1. Statistical Methods. Continuous variables are expressed
as means with standard deviations (SD) and minimum and
maximum values. Categorical variables are expressed as
percentages.
Univariate and multivariable binary logistic regression
analyses were performed to identify variables associated with
death. Variables with a univariate 𝑝 value < 0.10 were entered
into the multivariable models. Odds ratios (ORs) and 95%
confidence intervals (CIs) are reported.
Linear regression analysis was used to evaluate the inter-
action of dialysis dose and nPCR (Figure 1) and the material
was split into two groups on the basis of EKR/𝑉 and nPCR
(Table 3).
SPSS 22.0 and STATA 13.1 were used in statistical calcula-
tions. The graph was drawn with Excel 2007.
3. Results
The overall mortality was 140 per 1,000 patient years. The
main results are shown in Table 1. Mortality was significantly
associated only with EKR/𝑉 and nEKR. In multivariable
analysis, EKR/𝑉 was the only variable having an association
with death risk (OR = 0.326, CI = 0.117–0.912, and 𝑝 = 0.033).
Figure 1 illustrates the linear regression between nPCR
and EKR/𝑉. To eliminate the confounding effect of nPCR
on the dose-mortality relationship, the material was split
into two groups with approximately equal mean nPCR but
different mean EKR/𝑉. The line separating the groups is
depicted in Figure 1. Table 3 shows that the difference in
mortality between the low and high dose groups is still
significant.
Men had lower nPCR, EKR/𝑉, and stdK/𝑉 and higher
mortality thanwomen (Table 4). Diabetics had higherweight,
BMI, andBSAbut did not differ significantly fromnondiabet-
ics in mortality (Table 5).
Correlations between some patient characteristics and
continuous-equivalent clearances are shown in Table 6. All
clearances correlate with each other.
4. Discussion
The association of six continuous-equivalent urea clearance
measures with death risk was evaluated by statistical analysis.
The most significant predictor in univariate analysis and the
only significant one in multivariable analysis was EKR/𝑉,
calculated from TAC (𝑝 = 0.033). The 𝑝 value of stdK/𝑉
(from PAC) was 0.059. In the old NCDS, TAC had a closer
correlation with outcome than PAC [25].The stdK concept is
compliant with the peak concentration hypothesis [26], not
supported by the present results.
Normalizing with BSA was tested by the variables nEKR
and nstdK, with mL/min/1.73m2 (or L/week/1.73m2) as their
unit. nEKR was significantly associated with death risk, but
nstdK was not. In the present study, Kd was derived from
𝑄b, 𝑄d, and K0𝐴 reported by the dialyzer manufacturer.
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Table 4: Dialysis treatment periods by gender.
Women Men
𝑝 value
Mean SD Mean SD
Age Years 63.3 14.5 60.6 16.1 0.529
Weight kg 65.2 15.3 81.2 17.4 0.001
BMI kg/m2 25.7 5.9 26.3 5.3 0.694
BSA m2 1.66 0.17 1.95 0.22 <0.001
𝑉 L 26.1 3.6 35.3 5.7 <0.001
nPCR g/kg/day 1.23 0.23 1.10 0.24 0.043
nKr mL/min/1.73m
2 1.9 1.4 1.6 1.4 0.467
nEKR mL/min/1.73m2 12.4 1.1 12.7 1.5 0.401
nstdK mL/min/1.73m2 8.2 0.7 8.7 1.1 0.066
nEKRant mL/min/1.73m2 14.8 1.9 15.4 2.6 0.349
nstdKant mL/min/1.73m2 9.8 1.2 10.5 1.7 0.082
EKR/𝑉 /week 4.64 0.57 4.17 0.62 0.005
stdK/𝑉 /week 3.07 0.36 2.85 0.39 0.036
Treatment periods 𝑛 22 35
Ending with death % 13.6 37.1 0.055
Patient years 𝑛 50.6 63.7
Deaths 𝑛 3 13





















y = 1.50x + 2.66
y = 1.40x + 2.73
R2 = 0.29
Figure 1: Linear regression between nPCR and dialysis dose
(EKR/𝑉) and the line separating the groups of Table 3.
Calculated with Michaels’ equation [24], a 50% error in K
0
𝐴
causes an error of some 10% in Kd with usual 𝑄b and 𝑄d.
Errors in Kd cause in UKM proportional errors in 𝑉 and 𝐺.
In EKR/𝑉 and stdK/𝑉, the errors cancel each other out, but
not in nEKR and nstdK.
Two other BSA-normalized continuous-equivalent clear-
ances nEKRant and nstdKant were calculated applying the
method of Daugirdas et al. described in the Appendix [9,
27]. The anthropometric total body water is usually larger
compared to the kinetic 𝑉. Thus, nEKRant and nstdKant
are higher than the simple BSA-normalized values. They
are UKM-based continuous-equivalent hemodialysis dose
measures, where the possible errors in Kd are eliminated,
normalized with two anthropometric measures of body size
andwithmL/min/1.73m2 as unit. However, normalizingwith
BSA with either method did not improve the predictive value
of EKR/𝑉 and stdK/𝑉.
In the HEMO trial, the age-adjusted mortality did not
differ significantly between genders, but women did benefit
fromhigher dose [28]. In the present study, women had lower
mortality and got higher EKR/𝑉 and stdK/𝑉 but slightly
lower BSA-normalized doses (Table 4). Comorbidity other
than diabetes was not analyzed.
The rather wide range of dialysis doses in the present
study is probably due to the opportunistic aspect: more may
be better, but with large patients it is not easy to achieve a high
dose (Table 6). In Table 3, the distribution volume and the
proportion of men were higher in the low dose group. Men
had higher mortality and volume and lower𝑉-scaled dialysis
dose (Table 4).
The patient characteristics and dialysis dose measures
havemultiple correlations or dependencies (Table 6). Figure 1
shows the linear regression between nPCR and EKR/𝑉.
PCR is a function of EKR/𝑉 or stdK/𝑉 ((B.3) and (B.4)
in Appendix). Thus, mathematical coupling is inevitable. It
is also possible that nPCR depends on the dialysis dose
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Table 5: Dialysis treatment periods by diabetic status.
Diabetes
𝑝 valueYes No
Mean SD Mean SD
Age Years 61.2 14.9 62.0 16.1 0.842
Weight kg 81.7 18.5 70.2 16.7 0.018
BMI kg/m2 28.1 6.3 24.6 4.4 0.016
BSA m2 1.92 0.22 1.78 0.25 0.037
𝑉 L 32.9 6.3 30.9 6.9 0.260
nPCR g/kg/day 1.16 0.23 1.14 0.26 0.739
nKr mL/min/1.73m
2 1.5 1.0 1.9 1.6 0.243
nEKR mL/min/1.73m2 12.7 0.9 12.4 1.6 0.356
nstdK mL/min/1.73m2 8.6 0.8 8.4 1.1 0.350
nEKRant mL/min/1.73m2 15.8 1.9 14.6 2.5 0.055
nstdKant mL/min/1.73m2 10.7 1.3 9.9 1.7 0.047
EKR/𝑉 /week 4.43 0.47 4.29 0.74 0.427
stdK/𝑉 /week 2.99 0.27 2.89 0.46 0.360
Treatment periods 𝑛 24 33
Ending with death % 25.0 30.3 0.660
Patient years 𝑛 54.3 60.0
Deaths 𝑛 6 10
Mortality /1000 py 110 167 0.439
Table 6: Spearman’s correlations, significant at the 0.01 level (2-tailed).
Weight BMI BSA 𝑉 nPCR nEKR nstdK nEKRant nstdKant EKR/𝑉 stdK/𝑉
Weight 1 0.854 0.950 0.748 0.352 0.453 0.530
BMI 0.854 1 0.658 0.455 0.393 0.427
BSA 0.950 0.658 1 0.817 0.364 0.430 0.521
𝑉 0.748 0.455 0.817 1 0.436 −0.475 −0.354
nPCR 1 0.493 0.519 0.535 0.609
nEKR 1 0.929 0.694 0.711 0.566 0.631
nstdK 0.352 0.364 0.436 0.929 1 0.569 0.686 0.351 0.509
nEKRant 0.453 0.393 0.430 0.493 0.694 0.569 1 0.962 0.821 0.850
nstdKant 0.530 0.427 0.521 0.519 0.711 0.686 0.962 1 0.706 0.809
EKR/𝑉 −0.475 0.535 0.566 0.351 0.821 0.706 1 0.961
stdK/𝑉 −0.354 0.609 0.631 0.509 0.850 0.809 0.961 1
(causality) or that dosing of dialysis is guided by urea
concentrations or adjusted for protein catabolic rate [29] as
recommended by Gotch et al. [12, 30, 31] (reverse causality).
All these factorsmay have a role in the present study, but their
separate contribution could not be specified. In the HEMO
trial, the effect of dose on nPCR and the role of mathematical
coupling were estimated to be small [32].
PCR reflects dietary protein intake, which correlates with
nutritional status and outcome [33]. In a recent large registry
material mortality decreased with increasing nPCR until
1.3 g/kg/day [34]. Table 3 shows that in the present study
EKR/𝑉 had a significant association with mortality, although
nPCR was slightly higher in the low EKR/𝑉 group. nPCR
is associated with mortality directly and with the dialysis
dose through the “fear of high urea concentrations” effect—
an example of the mechanisms possibly underlying the dose-
targeting bias [35]. nPCR and dialysis dose may have a
synergistic effect on survival.
A limitation of the present study is the small number of
patients, which prevents robust conclusions. On the other
hand, different dosing definitions were compared in the same
material—a response to the challenge presented byDebowska
et al. [36].
In summary, EKR/𝑉 and nEKR were significantly associ-
ated with mortality but stdK/𝑉 and nstdK were not. Normal-
izing with BSA [9, 37] did not improve the significance of the
ECC measures.
Appendix
A. Continuous-Equivalent Clearance (ECC)





6 Advances in Nephrology





In EKR, 𝐶 is the time-average concentration (TAC) and, in








The unit is, for example, mL/min or L/week. Both may be
scaled to body size by dividing by urea distribution volume







𝐺, 𝑉, TAC, and PAC are determined by kinetic modeling,
in the present study with Solute-Solver. TAC and PAC are
whole-body water concentrations and 𝑉 is the postdialysis
total volume 𝑉
𝑡
. The most practical unit of EKR/𝑉 and
stdK/𝑉 is /week.
nEKR and nstdK are ECC values (ECCTA and ECCPA)
normalizedwith body surface area analogically to glomerular









Daugirdas et al. have developed a method to get a BSA-
normalized stdK𝑡/𝑉 [9, 27]:
SAn-stdK𝑡/𝑉 = stdK𝑡/𝑉 ∗ Vant
BSA ∗ 20
, (A.8)
where Vant is anthropometric TBW in liters, BSA is in m2,
and the constant 20 is the mean of 𝑉/BSA (L/m2) in their
material. Similarly, nEKRant and nstdKant can be calculated
by using a combined anthropometric scaling factor Vant/BSA
(=TBW/BSA):
nEKRant = EKR/𝑉 ∗ Vant
BSA
∗ 1.73, (A.9)
nstdKant = stdK/𝑉 ∗ Vant
BSA
∗ 1.73, (A.10)
with appropriate unit conversion factors. Vant/BSA takes
gender into account. In the present material, its average
value was 18.7 (18.3–20.3) L/m2 for women and 21.9 (20.2–
24.5) L/m2 for men.
B. nPCR
By definition (see (A.4) and (A.6)),
𝐺 = stdK/𝑉 ∗ PAC ∗ 𝑉. (B.1)
In hemodialysis, nPCR is generally calculated by the Borah
equation [38] with Sargent’s modification [39]:
nPCR = (9.35 ∗ 𝐺 + 0.294 ∗ 𝑉)
(𝑉/0.58)
, (B.2)
where nPCR is expressed in g/kg/day, 𝐺 is expressed in
milligrams of urea-N/min, and 𝑉 is expressed in L. By sub-
stituting 𝐺 from (B.1) and using appropriate unit conversion
factors we get
nPCR = 0.0151 ∗ stdK/𝑉 ∗ PAC + 0.171, (B.3)
where nPCR is in g/kg/day, stdK/𝑉 is in /week, and PAC is in
mmol/L. 𝑉 will be eliminated. nPCR is high if concentration
(PAC) is high despite high or normal clearance (stdK/𝑉).
stdK/𝑉 and PAC can be substituted with EKR/𝑉 and TAC:
nPCR = 0.0151 ∗ EKR/𝑉 ∗ TAC + 0.171. (B.4)
nPCR is inevitably correlated with stdK/𝑉 and EKR/𝑉. The
body surface area-normalized ECC measures are not so
closely associated with nPCR.
Abbreviations
BMI: Body mass index = weight/height2
BSA: Body surface area
𝐶: Concentration
ECC: Continuous-equivalent clearance
EKR: Equivalent renal clearance = 𝐺/TAC
EKR/𝑉: EKR scaled to 𝑉
eK𝑡/𝑉: Equilibrated K𝑡/𝑉






𝐴: Dialyzer mass area coefficient
K𝑡: Clearance ∗ session time
K𝑡/𝑉: K𝑡 scaled to distribution volume =
Kd ∗ 𝑡d/𝑉𝑡
nEKR: EKR normalized with BSA
(mL/min/1.73m2)
nEKRant: EKR normalized with BSA and Vant
(mL/min/1.73m2)
nKr: Kr normalized with BSA
(mL/min/1.73m2)
nstdK: stdK normalized with BSA
(mL/min/1.73m2)
nstdKant: stdK normalized with BSA and Vant
(mL/min/1.73m2)
nPCR: PCR scaled to normal body weight =
PCR/(𝑉/0.58) (g/kg/day)
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PAC: Average predialysis concentration, peak
average concentration
PCR: Protein catabolic rate (g/day)
py: Patient years
𝑄b: Dialyzer blood flow
𝑄d: Dialysate flow
RRF: Residual renal function
spK𝑡/𝑉: Single pool K𝑡/𝑉
stdK: Standard clearance = 𝐺/PAC
stdK/𝑉: stdK scaled to 𝑉
TAC: Time-averaged concentration
TBW: Total body water (Watson) = Vant
𝑡d: Dialysis session duration
UF: Ultrafiltration volume (positive, if fluid is
removed)
UKM: Urea kinetic model
𝑉: Distribution volume





The study was based on an analysis of register data collected
and utilized during the routine care of patients and conducted
with the permission of the medical director of the hospital.
There was no control group or randomization. The study
was not presented to an ethics committee because there
were no interventions and, according to Finnish law, registry
reports are not subject to evaluation by ethics committees.
The patient data were anonymized and deidentified prior to
analysis.
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